BidaskClub lowered shares of Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) from a strong-buy rating to a buy rating in a research note released on Wednesday.

Other research analysts have also recently issued research reports about the stock. TheStreet cut shares of Pieris Pharmaceuticals from a c- rating to a d- rating in a report on Monday, June 12th. Rodman & Renshaw assumed coverage on shares of Pieris Pharmaceuticals in a report on Tuesday, May 30th. They set a buy rating and a $9.00 target price for the company. Finally, Oppenheimer Holdings, Inc. set a $9.00 price target on shares of Pieris Pharmaceuticals and gave the company a buy rating in a research note on Wednesday, April 12th. Four research analysts have rated the stock with a buy rating, Pieris Pharmaceuticals presently has an average rating of Buy and a consensus target price of $8.00.

Pieris Pharmaceuticals (PIRS) opened at 5.32 on Wednesday. The stock’s 50 day moving average is $5.16 and its 200-day moving average is $3.36. The company’s market cap is $229.12 million. Pieris Pharmaceuticals has a 12-month low of $1.30 and a 12-month high of $6.20.

Pieris Pharmaceuticals (NASDAQ:PIRS) last announced its earnings results on Wednesday, May 10th. The biotechnology company reported ($0.19) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of $0.16 by $0.35. Pieris Pharmaceuticals had a negative return on equity of 95.10% and a negative net margin of 449.33%. The business had revenue of $1.34 million for the quarter, compared to analyst estimates of $32.30 million. Analysts predict that Pieris Pharmaceuticals will post ($0.69) earnings per share for the current fiscal year.

WARNING: “Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) Downgraded by BidaskClub” was originally published by Watch List News and is the sole property of of Watch List News. If you are reading this report on another publication, it was copied illegally and republished in violation of United States and international trademark and copyright laws. The legal version of this report can be viewed at https://www.watchlistnews.com/pieris-pharmaceuticals-inc-nasdaqpirs-downgraded-by-bidaskclub/1462475.html.

Hedge funds have recently made changes to their positions in the stock. Acadian Asset Management LLC bought a new position in shares of Pieris Pharmaceuticals during the second quarter valued at $162,000. Creative Planning raised its position in shares of Pieris Pharmaceuticals by 8.3% in the second quarter. Creative Planning now owns 65,000 shares of the biotechnology company’s stock valued at $329,000 after buying an additional 5,000 shares during the last quarter. Renaissance Technologies LLC bought a new position in shares of Pieris Pharmaceuticals during the first quarter valued at $661,000. Finally, Sphera Funds Management LTD. raised its position in shares of Pieris Pharmaceuticals by 23.5% in the first quarter. Sphera Funds Management LTD. now owns 1,000,000 shares of the biotechnology company’s stock valued at $2,600,000 after buying an additional 190,000 shares during the last quarter. Hedge funds and other institutional investors own 45.55% of the company’s stock.

Pieris Pharmaceuticals Company Profile

Pieris Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company’s pipeline includes immuno-oncology multi-specifics tailored for the tumor micro-environment, an inhaled Anticalin to treat uncontrolled asthma and a half-life-optimized Anticalin to treat anemia. Its Anticalins proteins are a class of low molecular-weight therapeutic proteins derived from lipocalins, which are naturally occurring low-molecular weight human proteins typically found in blood plasma and other bodily fluids.

Receive News & Ratings for Pieris Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pieris Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.